A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease.

Jaime Kulisevsky,Saul Martínez-Horta,Antonia Campolongo,Berta Pascual-Sedano,Juan Marín-Lahoz,Helena Bejr-Kasem,Jose L Labandeira-Garcia,Jose L Lanciego,Arnau Puig-Davi,Andrea Horta-Barba,Javier Pagonabarraga,Jon Rodríguez-Antigüedad

Parkinsonism & related disorders（2023）

引用 0|浏览17

暂无评分

摘要

•Angiotensin-II Type-I receptor blockers have shown neuroprotective evidence in PD.•They have also shown protective effects on cognitive impairment of different causes.•Candesartan was safe and well tolerated in PD with cognitive impairment.•There were no beneficial effects on cognition.•Positive effects on apathy, closely related to cognition, require further studies.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要